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Abstract
Various fungi of the genera Aspergillus, Penicillium, and Malbranchea produce prenylated indole 
alkaloids possessing a bicyclo[2.2.2]diazaoctane ring system. After the discovery of distinct 
enantiomers of the natural alkaloids stephacidin A and notoamide B, from A. protuberus MF297-2 
and A. amoenus NRRL 35660, another fungi, A. taichungensis, was found to produce their 
diastereomers, 6-epi-stephacidin A and versicolamide B, as major metabolites. Distinct 
enantiomers of stephacidin A and 6-epi-stephacidin A may be derived from a common precursor, 
notoamide S, by enzymes that form a bicyclo[2.2.2] diazaoctane core via a putative intramolecular 
hetero-Diels–Alder cycloaddition. This review provides our current understanding of the structural 
and stereochemical homologies and disparities of these alkaloids. Through the deployment of 
biomimetic syntheses, whole-genome sequencing, and biochemical studies, a unified biogenesis of 
both the dioxopiperazine and the monooxopiperazine families of prenylated indole alkaloids 
constituted of bicyclo[2.2.2]diazaoctane ring systems is presented.
1. Introduction
The isolation of natural products from marine and terrestrial-derived fungal species of the 
Aspergillus, Penicillium and related genera has allowed for a widely studied diverse class of 
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secondary metabolites. In particular, various prenylated indole alkaloids have been 
discovered, including the brevianamides,1–7 marcfortines,8,9 paraherquamides,10–14 
penicimutamides,15 sclerotiamide,16 asperparalines,17 avrainvillamide,18,19 stephacidins,20 
malbrancheamides,21–23 notoamides,24–27 versicolamide B,28 chrysogenamide,29 and 
recently the taichunamides (Fig. 1).30 The presence of a bicyclo[2.2.2]diazaoctane ring 
system and densely functionalized indole-derived units form the bases for the structural 
allure of these naturally occurring metabolites. Many of these alkaloids have been found to 
show a variety of biological activity including insecticidal, cytotoxic, anthelmintic, 
calmodulin inhibition,31 osteoclast inhibition, and antibacterial properties.1–3,5,8–30,32–34 
Reviews in this area have included the studies on the discovery of unexpected enantiomeric 
and diastereomeric relationships (Fig. 2) (see Section 2) as well as developments in the 
biosynthesis of these compounds (see Section 3), and biomimetic total syntheses (see 
Section 4).35–41 Herein, this review will focus on the biogenesis of the notoamides and their 
congeners, and provide the current understanding of the structural and stereochemical 
homologies and disparities that are particularly intriguing from a biosynthetic perspective.
Elucidation of the biogenesis of these compounds became of particular interest upon the 
isolation of antipodal metabolites from different species of the Aspergillus genus from both 
marine and terrestrial sources. Initial studies from the Williams laboratory42 were based on 
seminal work first reported by Sammes43 and Birch,44 and demonstrated that these natural 
metabolites arise from L-tryptophan, one or two isoprene units, and L-proline, β-
methylproline, or pipecolic acid.
The first proposal concerning the biogenesis of the bicyclo [2.2.2]diazaoctane ring system 
was that of Sammes in 1970,43 wherein the intermediacy of an intramolecular hetero Diels–
Alder construction through the agency of an azadiene species was proposed (left, Fig. 3). 
Shortly thereafter, Birch inferred in 1971 (ref. 45) the intermediacy of an 
epidithiapiperazinedione species, with net extrusion of S2 to form this ring system (right, 
Fig. 3), although the nature of the C–C bond formations as being heterolytic, radical, or 
stepwise were not further discussed.
At the time of the Sammes and Birch publications in the early 1970's, the absolute 
configuration of brevianamide B had not been rigorously assigned, but was thought to be of 
the same absolute sense as that of brevianamide A and being diastereomeric at the spiro-
indoxyl stereogenic center. The Williams laboratory, in 1988,46 completed the first synthesis 
of (−)-brevianamide B and re-assigned the absolute configuration of natural (+)-
brevianamide B, as depicted in Fig. 1.47,48 This revealed that brevianamides A and B have a 
pseudo-enantiomeric relationship (that is, the tricyclic portion constituted with the 
bicyclo[2.2.2]diazaoctane ring system are enantiomeric, but brevianamides A and B are 
technically diastereomers) which immediately raised provocative questions regarding the 
biogenesis of these natural substances in Penicillium brevicompactum. Williams suggested a 
modification to the intramolecular hetero Diels–Alder proposal, originally postulated by 
Sammes,43 as shown in Scheme 1.39,49,50 The differences between the Sammes and 
Williams biogenetic constructions involves the timing of the indole oxidation relative to the 
IMDA reaction. The Sammes proposal invokes a spiro-5 IMDA construction whereas the 
Williams alternative requires a spiro-6 IMDA. The Williams lab interrogated their alternative 
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hypothesis through the synthesis and attempted precursor incorporation of DL-1. This 
potential metabolite was not incorporated into either brevianamide A nor brevianamide B in 
Penicillium brevicompactum,51,52 leaving the Sammes proposal as the most plausible. 
However, advances in confirming the assembly details of these fungal indole alkaloids were 
only made possible with identification of the notoamide gene cluster (see Section 3) as well 
as through labeled precursor incorporation studies of anticipated intermediates (see Section 
2).
A deeper understanding of the enantio- and diastereo-divergence of the biosynthetic 
pathways exhibited by these closely related fungi, has led to the proposal of the functional 
presence of enzymes putatively mediating a Diels–Alder-type construction, an enzymatic 
function that is now receiving considerable attention from a number of laboratories 
investigating natural products biosynthetic pathways.53 Theoretical54,55 and 
experimental56–61 studies from our laboratories have provided corroborating evidence that 
an enzyme-mediated IMDA reaction is operative in the biosynthesis of the bicyclo 
[2.2.2]diazaoctane ring systems.38,53
2. Fungal metabolites and biosynthetic studies of prenylated 
bicyclo[2.2.2]diazaoctane indole alkaloids
As to be discussed in detail below, there exists striking stereochemical similarities and 
differences between various members of this family of alkaloids for which biogenetic 
constructions need to accommodate. With respect to the construction of the 
bicyclo[2.2.2]diazaoctane ring system, the progenitor dioxopiperazine 4 (X = O) (or, for the 
paraherquamides, marcfortines, asperparalines, and malbrancheamides, the progenitor 
monooxopiperazine, 4, X = H2) suffers a net two-electron oxidation allowing the pendant 
isoprene-derived vinyl moiety to form the two new C–C bonds of the 
bicyclo[2.2.2]diazaoctane ring system. Four distinct diastereomeric transition states for this 
process can be operative resulting in the syn- (5) or anti-(6) diastereomeric relationships and 
a more subtle outcome being the manifestation of top-face or bottom-face cycloaddition as 
generically summarized in Fig. 4.
These stereochemical outcomes can be specifically identified in the known metabolic fates 
of notoamide S as illustrated in Scheme 2.61,63 Various metabolites have been identified, 
which were biosynthesized through both enantiomers of notoamide T and 6-epi-notoamide 
T.27,30,61,63–65 It has been suggested that all four of these substances arise via the 
intermediacy of common achiral azadiene species 7 (Scheme 2).
2.1 Isolation of prenylated indole alkaloids from the marine- derived fungus A. protuberus 
MF297-2 and the first proposal of the biogenesis of these alkaloids
The marine-derived fungus A. protuberus MF297-2 was isolated from the mussel Mytilus 
edulis galloprovincialis, which was collected from the Noto peninsula (Japan) by the 
Tsukamoto laboratory. The fungal culture showed the activity of cell cycle inhibition in 
HeLa cells and the bioassay-guided purification afforded a fungal toxin, sterigmatocystin, as 
a cell cycle inhibitor along with seven prenylated indole alkaloids. Structure elucidation 
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revealed that four of these were new alkaloids, notoamides A–D, and three were known 
alkaloids, sclerotiamide, stephacidin A, and deoxybrevianamide E.1,24 The structural 
relationship of these alkaloids led to the first proposal of the biosynthetic pathway illustrated 
in Scheme 3.66,67 Notoamide E was suggested to be a key precursor for this family, although 
it had not yet been isolated from the culture. The compounds containing a bicyclo 
[2.2.2]diazaoctane nucleus, namely stephacidin A, notoamides A and B, and sclerotiamide, 
were hypothesized to be produced from notoamide E through an achiral azadiene 
intermediate 8 by the IMDA reaction.
2.2 Precursor incorporation studies of notoamide E and structurally novel metabolites 
from A. protuberus MF297-2
Since notoamide E was identified as a key intermediate in the biosynthesis of prenylated 
indole alkaloids in A. protuberus, Tsukamoto, et al. searched for notoamide E in the culture 
and found that it existed only in the fifth day of culture growth and immediately disappeared 
the next day.68,69 These results clearly indicated that notoamide E was produced by the 
fungus in the early phase of growth and was presumably rapidly converted to other 
downstream metabolites. Subsequently, precursor incorporation experiments with synthetic, 
[13C]2–notoamide E were carried out.68,71 Surprisingly, it was converted only to notoamides 
C and D as well as four new alkaloids, 3-epi-notoamides C and notoamides E2–E4, but not 
to the alkaloids containing a bicyclo[2.2.2]diazaoctane core, such as stephacidin A, 
notoamides A and B, nor sclerotiamide (Fig. 5).
Furthermore, in a precursor incorporation experiment, [13C]2–(+)-stephacidin A was, as 
expected, converted to (−)-notoamide B and (−)-sclerotiamide (Scheme 3).70 The four new 
alkaloids (3-epi-notoamide C and notoamides E2–E4) were not detected as metabolites from 
this organism in the normal nutrient-rich medium. Among these, the structure of notoamide 
E4 is particularly interesting, and two possible biosynthetic pathways from notoamide E can 
reasonably accommodate the biogenesis of these species (Scheme 4).68 One of the possible 
pathways would proceed via dioxetane intermediate 9, followed by fragmentation to the 
corresponding kynurenine derivative 10. Then, cyclization of 10 would afford the eight-
membered ring derivative, notoamide E4. An alternative pathway is via peroxide species 11, 
which would be produced by proton-assisted nucleophilic attack of the indole 3-position on 
molecular oxygen. The results of this precursor incorporation experiment reveals that the 
addition of excess [13C]2–notoamide E (an endogenous metabolite) above the concentration 
levels of this metabolite normally produced, appears to alter the secondary metabolite profile 
of this organism. This provocative result warrants further investigation into how notoamide 
E, at elevated concentrations, must trigger the expression of dormant tailoring genes present 
that are not expressed under normal growth conditions.
Tsukamoto, et al. succeeded in the isolation of notoamides M26 and Q,27 which have 
hydroxy and methoxyl groups at C-17 positions, respectively (Scheme 5). These metabolites 
represent the oxidation state of the putative azadiene species that have been strongly 
implicated in the construction of the bicyclo [2.2.2]diazaoctane ring system. Thus, it is 
possible that formation of azadiene intermediate (D), proceeds through oxidation at C-17 of 
dioxopiperazine A to B, followed by loss of water or methanol and tautomerization to D 
Klas et al. Page 4
Nat Prod Rep. Author manuscript; available in PMC 2018 August 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(Scheme 5). Alternatively, notoamides M and Q, might be artifacts of hydration/capture of 
azadiene species (C) and experiments to interrogate this possibility are being investigated.
Tsukamoto, et al. isolated eighteen new prenylated indole alkaloids, notoamides A–R,24–27 
from the marine fungus A. protuberus. Among these, carbon frameworks of notoamides L26 
and O27 were novel in the family of prenylated indole alkaloids and notoamides N26 and P27 
contained chlorine and bromine atoms, respectively (Fig. 6). Notoamide L is the first 
metabolite containing twenty-five carbons in this family, while all other alkaloids possess 
twenty-six carbons. In the structure of notoamide L, the C-2 carbon derived from tryptophan 
has been removed.
Notoamide O possesses a novel hemiacetal/hemiaminal ether functionality hitherto unknown 
among this family. Possibly, notoamides L and O may be derived from (+)-stephacidin A 
(Scheme 6). In the biogenesis of notoamide L, singlet oxygen reaction at the indole 2,3-
position of (+)-stephacidin A would afford a dioxetane intermediate 12 followed by 
fragmentation to kynurenine 13. After hydrolysis of the amide bond of 13, oxidation at C-24 
followed by decarboxylative dehydration would afford notoamide L.26 On the other hand, 
stephacidin A may be converted to aspergamide B72 via notoamide R. Oxidative cleavage of 
the tri-substituted alkene in aspergamide B would generate aldehyde hydrate 16; simple ring 
closure would afford notoamide O.27 Notoamide N is one of the rare chlorinated members of 
the family of prenylated indole alkaloids and this is the third chlorinated derivative following 
malbrancheamide,21 malbrancheamide B22 and spiromalbramide.23 On the other hand 
notoamide P is the first brominated member of this family.27,65 The existence of a 
halogenase system in these fungi is of interest and the identification of the genes responsible 
for the halogenations merits further investigation.
2.3 Isolation of enantiomers of stephacidin A and notoamide B from the terrestrial fungus 
Aspergillus amoenus NRRL 35660
The Gloer laboratory originally isolated (−)-stephacidin A and (+)-notoamide B from the 
terrestrial fungus A. amoenus (formerly A. versicolor) NRRL 35660, which was isolated 
from a basidioma of Ganoderma australe collected in a Hawaiian forest, along with a new 
alkaloid, (+)-versicolamide B (Fig. 2).28 (+)-Stephacidin A was originally isolated from the 
terrestrial fungus A. ochraceus by Bristol-Myers Squibb20 and subsequently, (+)-stephacidin 
A and (−)-notoamide B were isolated from the marine-derived fungus A. protuberus 
MF297-2, by the Tsukamoto laboratory.24 These facts reveal that these closely related 
Aspergillus fungi biosynthesize the opposite enantiomers of stephacidin A and notoamide B 
and it has been confirmed that the optical purity of these metabolites are >99%. The initial 
hypothesis for rationalizing how these opposite enantiomers might arise, is illustrated in 
Scheme 7 and invokes the oxidation of notoamide E, to the achiral azadiene species 8, 
followed by an entirely enantio-selective cycloaddition from this common precursor.28 
Although [13C]2–stephacidin A was converted to [13C]2–notoamide B,70 as discussed above, 
the incorporation of [13C]2–notoamide E into stephacidin A and notoamide B, however, was 
not observed in A. amoenus73 nor A. protuberus.68 These results suggested alternate timing 
of the pyran and bicyclo[2.2.2]diazaoctane ring constructions as discussed below.
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2.4 An alternative enantiodivergent biosynthetic pathway for stephacidin A biogenesis
Since [13C]2–notoamide E was not incorporated into stephacidin A in either A. protuberus 
MF297-2 nor A. amoenus NRRL 35660, other testable hypotheses needed to be devised. 
The pathway from deoxybrevianamide E to stephacidin A contains four steps: the putative 
IMDA, an oxidation at C-6, prenylation, and final oxidation/cyclization to form a pyran ring 
(Scheme 8). From the results of the precursor incorporation experiments with notoamide E, 
three compounds, namely deoxybrevianamide E, 6-hydroxy-deoxybrevianamide E, and 
notoamide S, appeared to be potential precursors for IMDA reactions, although notoamide S 
had not yet been isolated from any species of the Aspergillus fungi.74 The incorporation 
experiments of synthetic [13C]2–[15N]–deoxybrevianamide E75 and [13C]2–[15N]–6-
hydroxydeoxybrevianamide E75,76 afforded notoamides C and D but not stephacidin A nor 
notoamides A and B. Next, the administration of synthetic [13C]2–[15N]2–notoamide S in A. 
amoenus was examined and it was found to be incorporated into (−)-stephacidin A (6.2% 
incorporation), (+)-notoamide B (6.4% incorporation), and (+)-versicolamide B (6.5% 
incorporation), together with notoamides C (6.4% incorporation) and D (6.2% 
incorporation) (Fig. 7).77 These results clearly indicated that the construction of the 
bicyclo[2.2.2]diazaoctane ring system occurs prior to the formation of the pyran ring. 
Although notoamides S and T had not previously been found in the culture extract of A. 
amoenus, Kato, et al., have recently identified notoamide S as a minor metabolite of A. 
amoenus.61
2.5 The incorporation of notoamide T and 6-epi-notoamide T
Since notoamide S was observed to be converted to compounds containing a 
bicyclo[2.2.2]diazaoctane core via notoamide T and 6-epi-notoamide T (Scheme 2), the 
precursor incorporation experiments of these two alkaloids were performed. Unexpectedly, 
the administration of synthetic [13C]2–(±)-notoamide T in A. protuberus aff orded racemic 
mixtures of stephacidin A, notoamide B, notoamide F, notoamide R, and a new compound, 
notoamide T2 (Fig. 8A).63 On the other hand, synthetic [13C]2–6-epi-(±)-notoamide T was 
converted to racemic mixtures of versicolamide B and eight new compounds, 6-epi-
notoamides T3–T8 and 6-epi-notoamide I, in a trace element solution (Fig. 8B) and afforded 
racemic mixtures of 6-epi-stephacidin A and four new compounds, 6-epi-notoamides T9–
T12, on trace element agar plates (Fig. 8C).64
Among them, notoamide T2, 6-epi-notoamides T3–T12, and 6-epi-notoamide I were not 
produced by the fungus under normal culture conditions to any detectable extent.63,64 These 
data suggest that the (presumably) endogenous, natural metabolites [13C]2–(±)-notoamide T 
and [13C]2–(±)-6-epi-notoamide T activated the expression of dormant tailoring genes that 
expands the metabolome of the producing organism. While notoamide T and 6-epi-
notoamide T are presumed to be natural, endogenous metabolites in this organism, the 
precursor incorporation experiment with the easily accessible synthetic, racemic labeled 
substances was performed. In order to further interrogate this fascinating observation, 
sufficient quantities of the respective optically pure enantiomers of each will be required to 
query whether the metabolite profile alteration is triggered by the presence of the unnatural 
enantiomer for this producing organism.
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Of particular intrigue, 6-epi-notoamides T3 and T4 contain unprecedented structures 
wherein the aromatic benzenoid ring of the tryptophan moiety has suffered oxidative 
amination, culminating in the formation of the new fused oxazole and 2-oxazolone moieties, 
respectively. One possible mechanism for the oxidative amination of the tryptophan moiety 
is suggested in Scheme 9. Oxidation and subsequent pinacol rearrangement of [13C]2–(±)-6-
epi-notoamide T would form the spiro-oxindole, [13C]2–(±)-6-epi-notoamide T9. Successive 
oxidation and incorporation of glycine into 20 to form imine 21, followed by 
decarboxylation, provides 22 that must cyclize (to 23) and then be oxidized to the oxazoline 
moiety of T3. Oxidation of the oxazoline of T3 would produce oxazolidinone in 6-epi-
notoamide T4.64 It is reasonable to assume that the initial oxidation of the 2,3-disubstituted 
indole of 6-epi-notoamide T is conducted by NotI that Li, et al., previously predicted this 
oxidation and spiro-rearrangement.62 The downstream transformations from 6-epi-
notoamide T9, requires a minimum of six enzyme-catalyzed reactions: (1) aromatic 
hydroxylase of T9 to 19; (2) a catechol oxidase to 20; (3) glycine aminotransferase to 21; (4) 
decarboxylase/cyclase to 23; (5) oxazolidine oxidase to T3; and (6) oxazolidinone oxidase to 
T4. The complex array of transformations required to construct T3 and T4 from 6-epi-
notoamide T mandates that multiple dormant tailoring genes extant in this organism were 
activated by the presence of one (or both) enantiomers of 6-epi-notoamide T. Significant 
effort will need to be devoted to elucidating the nature of these remarkable transformations 
that have significant implications for the plasticity of secondary metabolomes in Nature.
2.6 Isolation of an enantiomeric mixture of 6-epi- stephacidin A from A. amoenus NRRL 
35660
The metabolic profiles of A. protuberus MF297-2 and A. amoenus. NRRL 35660 produced 
the opposite enantiomers of stephacidin A and notoamide B along with the same enantiomer 
of (+)-versicolamide B. (−)-Versicolamide B has yet to be detected as a natural metabolite in 
any of the fungi that have been examined to date and poses an enigma (Fig. 2). (+)-6-epi-
Stephacidin A is the likely precursor of (+)-versicolamide B and was obtained from the 
culture of A. protuberus (Scheme 10).64 However, 6-epi-stephacidin A, which was isolated 
from A. amoenus, was found to be an enantiomeric mixture enriched with the (−)-isomer (1 : 
2.4).61 This result clearly suggested that, in A. amoenus, notoamide S was converted to both 
(+)- and (−)-6-epi-stephacidin A and subsequently, only the (+)-isomer was converted into 
(+)-versicolamide B (Scheme 10). This result mandates that A. amoenus contains a highly 
enantio-specific indole oxidase that exclusively transforms the (+)-enantiomer of 6-epi-
stephacidin A to (+)-versicolamide B, but apparently does not bind or oxidize the (−)-
enantiomer of 6-epi-stephacidin A. While the formation of an enantiomerically-enriched 
metabolite has not yet been observed in any of the other fungal species examined, this begs 
the question of why this occurs in A. amoenus. The lack of optical purity of 6-epi-
stephacidin A obtained in A. amoenus also requires an explanation and it is to such 
questions, that our labs have recently started investigations.
2.7 Isolation of taichunamides A–G from Aspergillus taichungensis IBT 19404: biogenetic 
considerations
The majority of the prenylated indole alkaloids thus far identified containing the 
bicyclo[2.2.2]diazaoctane ring system possess the syn-configuration (the syn- and anti-
Klas et al. Page 7
Nat Prod Rep. Author manuscript; available in PMC 2018 August 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
relationship is based on the relative configuration of H21 with respect to the bridging 
secondary amide; see Fig. 4 and 9). Distinct enantiomers of notoamide B and stephacidin A 
are the main metabolites present in A. protuberus and A. amoenus, and (+)-versicolamide B, 
a minor metabolite, was the first alkaloid identfied within this family with the corresponding 
anti-configuration. In 2013, Cai et al. isolated (+)-versicolamide B and (+)-6-epi-stephacidin 
A as major metabolites from A. taichungensis ZHN-7-07.78 Kagiyama, et al., have also 
investigated the isolation of alkaloids from A. taichungensis IBT 19404 collected from the 
soil in Taiwan and succeeded in isolating seven indole alkaloids with unprecedented 
structures and have named these substances taichunamides A–G (Fig. 10); all of these 
natural alkaloids possess the anti-bicyclo[2.2.2]diazaoctane core.30 Although the structure of 
taichunamide A was initially assigned to contain a very rare azetidine unit, recently it was 
revised as a 3-hydroxyindolenine.79 Taichunamide B was found to be constituted with a very 
rare 4-pyridone unit. In DMSO-d6 taichunamide B appears to be an equilibrium mixture of 
two tautomeric entities: a 4-pyridone and 4-pyridol, in a ratio of 3 : 1. This tautomeric 
equilibrium is highly solvent-dependent where it was observed a single keto or enol form 
was observed in CD3OD or acetone-d6, respectively. Taichunamides C and D contain 
endoperoxide and methylsulfonyl units, respectively.
These new alkaloids, especially taichunamide B, constitute hitherto unknown structural 
arrays derived from tailoring of the tryptophan moiety and therefore must deploy a series of 
fascinating biochemical bond constructions. Biogenetic implications for taichunamides B 
and E as well as (+)-versicolamide B are represented in Scheme 11.30 β-Face oxidation 
(anti- to the bridged amide) of 6-epi-stephacidin A allows for the formation of a non-
isolatable epoxide intermediate 24 which subsequently undergoes a pinacol rearrangement 
within the active site to form the spirooxindole in (+)-versicolamide B. Oxidation at the α-
face (syn to the bridged amide) followed by pinacol rearrangement would allow for 
formation of taichunamide E. Compared with β-face oxidation, α-face oxidation is more 
sterically demanding with N19, as reflected by the metabolite ratios of (+)-versicolamide B 
(15.9 mg)/(+)-versicolamide C30,80 (a N1-OH derivative of versicolamide B)81 (240 mg) 
versus taichunamide E (0.43 mg). Although, in the biomimetic synthesis that deployed the 
IMDA reaction, taichunamide E was identified along with (+)-versicolamide B in a ratio of 
1 : 1.4; this is the first report of its isolation from the fungal culture.30 Also, formation of 
peroxide 26 by oxidation of (+)-6-epi-stephacidin A would ultimately lead to the ring system 
found in taichunamide B, theoretically through compound 27.
A wide structural array of prenylated indole alkaloids have been isolated from the genera of 
Aspergillus and Penicillium to date, yet their respective carbon frameworks are very unique. 
The isolation of these compounds from A. taichungensis has greatly expanded the library of 
these secondary metabolites. Future biochemical studies and genome mining will aid in the 
identification of genes or gene clusters responsible for the evolution of these unprecedented 
metabolites.
2.8 Biogenetic implications of prenylated indole alkaloids in the Aspergillus genus
To date, numerous fungal species in the Aspergillus genus, including A. ochraceus, A. 
protuberus MF297-2, A. amoenus NRRL 35660, and A. taichungensis IBT 19404, described 
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in this article that produce prenylated indole alkaloids, bearing the dioxopiperazine-based 
bicyclo[2.2.2]diazaoctane core most likely biosynthesized by the oxidative cycloaddition 
reaction of the common precursor, notoamide S (Scheme 12), have been identified. Each 
organism displays its own unique stereochemical signature wherein the absolute and relative 
stereochemistry within these molecular frameworks have been constructed are evident. In A. 
protuberus, the orientation of the dienophile to the diene in pathways a (main) and b 
(minor), respectively, leads to the construction of the corresponding exo-and endo-products 
namely, (+)-stephacidin A/(−)-notoamide B and (+)-6-epi-stephacidin A/(+)-versicolamide 
B, respectively. On the other hand, in A. taichungensis, the construction of the 
bicyclo[2.2.2]diazaoctane ring system favors the formation of the C-6-epi-diastereomeric via 
pathway b (main) and c (minor).30 Efforts to clarify the genetic and biochemical bases and 
relationships between the respective biosynthetic gene clusters are currently under intense 
investigation in our laboratories.
3. Genomic insights
In order to obtain a deeper understanding of the biogeneses of these structurally fascinating 
natural alkaloids, and in particular, to obtain a higher level elucidation of the 
enantioselectivity and diastereoselectivity evident in the biogenesis of the stephacidins and 
notoamides, the genomes of ten fungi known to produce these alkaloids have been 
sequenced and the identification of relevant biosynthetic gene clusters (Fig. 11) has been 
realized. The mining of ftmA, a NRPS gene from the fumitremorgin Aspergillus species, A. 
fumigatus, and production of brevianamide F by heterologous gene expression in 2006 by 
Turner et al.,82 allowed Ding, et al., to identify the notoamide gene cluster in A. protuberus.
83
 Due to the crucial role brevianamide F plays in the early biogenesis of an enormous range 
of prenylated indole alkaloids within the Aspergillus genus, it was originally assumed that 
ftmA, or a comparable homolog, would also participate in biosynthetic transformations of A. 
protuberus. Using Roche 454FLX technology and ftmA to probe for homologous genes, 
notE was identified as the NRPS module analogous to ftmA, sharing a 47% nucleotide 
identity, in the A. protuberus species.83 Fig. 12 represents the (+)- and (−)-notoamide-
producing gene clusters identified by genome sequencing and bioinformatics.83
Bioinformatics analysis83 and deep annotation, has revealed a number of important facts and 
relationships between A. protuberus and A. amoenus that produce the opposite enantiomers 
of stephacidin A and notoamide B. First, it is clear from the structure and directionality of 
the open-reading frames of genes within the gene clusters, that the gene clusters and thus the 
organisms are orthologous (ancestrally related through a speciation event that occurred at 
some time during their evolutionary history). The high level of nucleotide identity overall 
between the gene clusters is almost 71% and within individual genes, the homology with 
respect to amino acid identity or similarity, is as high as 95% (for example NotC). Functions 
have been assigned to a number of genes within these orthologous gene clusters and are 
identified in Fig. 12, Scheme 13, and Table 1 which reflects our current understanding and 
hypotheses regarding the biogenesis of the enantiomeric pairs.63,83
Li, et al., have successfully been able to clone and functionally express the following 
enzymes: NotF, NotG, NotC, NotD, NotD´, NotI and NotI´.62,83 Table 1 provides a 
Klas et al. Page 9
Nat Prod Rep. Author manuscript; available in PMC 2018 August 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
summary of the relevant data on each individual gene and the heterologous host in which the 
protein was functionally expressed.
Li, et al., have tentatively assigned roles to other genes in the notoamide gene clusters as 
follows. NotG appears to be a cytochrome P450 oxidase responsible for the transformation 
of deoxybrevianamide E into 6-hydroxydeoxybrevianamide E, which was deduced through a 
process of elimination by comparative analysis with several fungal gene clusters.62,83 The 
other cytochrome P450, NotH is the current most plausible candidate for the oxidative 
transformation of notoamide S into notoamide T and 6-epi-notoamide T.83 Much to our 
chagrin, NotH and NotH´, which is currently the focus of where the key enantiodivergence 
occurs, is a membrane-associated cytochrome P450 that has proven recalcitrant to functional 
expression in a heterologous host and constitutes the focus of our current efforts.
Biochemical characterization, along with isotopically labeled precursor incorporation studies 
(vide supra), has determined the roles of NotF and NotC as aromatic prenyltransferases.83 
Michaelis–Menten kinetics and isotopically labeled precursor incorporation studies have 
successfully demonstrated the substrate selectivity of the NotF and NotC enzymes. The 
reverse-prenylation of brevianamide F into deoxybrevianamide E, the first committed step of 
the post-NRPS tailoring cascade, is catalyzed by NotF. The subsequent normal prenylation 
of 6-hydroxydeoxybrevianamide E into notoamide S is catalyzed specifically by NotC.83
NotB and NotI are flavin-dependent monooxygenases (FMO) Biochemical characterization 
of NotB has determined its role as an FAD-dependent oxidase for converting notoamide E 
into notoamides C and D (Scheme 14).77 Curiously, 3-epi-notoamide C is not observed as a 
product when notoamide E is exposed to recombinant NotB. 3-epi-Notoamide C has been 
previously isolated from a precursor incorporation experiment with notoamide E as an added 
substrate, but has not been directly isolated from fermentation extracts of Aspergillus 
protuberus.68 NotI and NotI´ which are also flavin-dependent oxygenases, are predicted to 
catalyze the oxidative spiro-transformation of stephacidin A into notoamide B.83 The details 
of how NotI and NotI´ discriminate between the respective enantiomers of stephacidin A and 
the conversion into the corresponding enantiomers of notoamide B is of great interest, but 
has not yet been reported.
4. Biomimetic total syntheses
With the objective of interrogating the validity of the proposed biosynthetic intramolecular 
hetero Diels–Alder construction of the characteristic bicyclo[2.2.2]diazaoctane ring nucleus, 
Williams, et al., have investigated the laboratory version of the IMDA construction which 
successfully enabled biomimetic syntheses of numerous members of these natural alkaloids. 
These investigations provided additional insights as to the intrinsic facial bias of this 
cycloaddition with respect to the syn-/anti-diastereoselectivity.56–60 Theoretical calculations 
on these azadiene IMDA reactions published by our collaborator Domingo et al.,54,55 
provide an important backdrop to the laboratory and putative biosynthetic constructions. The 
strategies for generating the key azadiene species evolved to ever more efficient protocols 
over the years and are shown here chronologically. Our first successful biomimetic synthesis 
was that of D,L-brevianamide B, as shown in Scheme 15, where DDQ oxidation of lactam 
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ether 31 was employed to provide the unsaturated proline derivative 32.85 Base-mediated 
tautomerization generated the desired azadiene species, that proved stable enough to observe 
by 1H NMR, but spontaneously suffered IMDA cycloaddition to provide an approximately 
2 : 1 syn : anti mixture of cycloadducts 34 and 35, respectively. Peracid oxidation to the 
corresponding diastereochemically pure 3-hydroxyindolenines (36 and 37) followed by 
base-mediated pinacol-type spiro-rearrangement and final acidic removal of the lactim ether 
furnished D,L-brevianamide B from 37 and the corresponding syn-diastereomer 38.85
A second-generation synthesis, detailed in Scheme 16, generated the azadiene directly from 
an α-ketoamide proline amide species (i.e., 42).86 The IMDA reaction, carried out under 
strongly Lewis acidic conditions, interestingly provided the desired anti-cycloadduct 44, 
exclusively. Fisher indole synthesis to 46 and final peracid oxidation to the indoxyl provided 
D,L-brevianamide B.86
The most efficient biomimetic synthesis of brevianamide B that has been developed and 
reported to date, relied on using β-hydroxyproline as a surrogate representing the oxidation 
state of the azadiene, as shown in Scheme 17.60,85 Reverse-prenylated tryptophan species 47 
was coupled with β-hydroxyproline ethyl ester to give dipeptide 48 that was deprotected and 
cyclized to 49. Mitsunobu dehydration of 49 in dichloromethane at 40 °C led directly to the 
production of meta-stable azadiene species 50 that spontaneously underwent IMDA 
cycloaddition to give a 2.1 : 1, syn : anti diastereomeric mixture that were readily separated 
by chromatography. The minor anti-cycloadduct 46 was subjected to peracid oxidation as 
above and rearranged under basic conditions furnishing D,L-brevianamide B. It is important 
to note that the intrinsic facial bias of the IMDA cycloadditions in all cases, was about 2 : 1 
favoring the syn-diastereomer and in good agreement with theoretical predictions published 
by our collaborator Prof. Domingo (see below). The intrinsic facial bias of these IMDA 
reactions, have been interrogated by Domingo, et al., quantum chemically at the B3LYP/
6-31G* level.54 He has examined both the dioxopiperazine-based azadienes (51b; 54b) 
relevant to the stephacidin and notoamide families, as well as the corresponding 
monooxopiperazine-based azadienes (51a; 54a) relevant to the paraherquamide, 
malbrancheamide and related family members.
As depicted in Scheme 18, two main substrate platforms were evaluated: the spiro-5 mode, 
wherein the indole has been oxidized to the corresponding oxindole species and the spiro-6 
mode, wherein the indole has yet to suffer oxidative tailoring.54 Strikingly, it was found that 
the spiro-5 mode greatly favors the anti-diastereomer (52) over the corresponding syn-
diastereomer (53) by 4–7 kcal mol−1. In contradistinction, the corresponding spiro-6 mode 
from 54, revealed a modest preference for the syn- diastereomers 56 by about 1 kcal mol
−1
.
54
 These theoretical predictions have tracked quite well with experiment as can be seen 
from the modest syn : anti diastereoselectivities for the laboratory spiro-6 systems described 
above and below, where the syn : anti ratio is typically around 2.5 : 1. On the other hand, the 
experimentally observed spiro-5 cycloadditions have to date, yielded exclusively the anti-
diastereomers, which will be detailed below.
The biomimetic syntheses developed above for brevianamide B, set the stage for deploying 
this technology to prepare more complex members of this family. The Williams lab has been 
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able to successfully devise a biomimetic total synthesis of stephacidin A and its C-6-epimer, 
and more recently demonstrated C6-epi-stephacidin A to be a natural metabolite and, as 
noted above, these stephacidin A congeners are the direct biosynthetic precursors to 
notoamide B and versicolamide B, respectively. Subsequent to the biomimetic stephacidin A 
synthesis, these workers have been able to readily adopt this approach for successful 
biomimetic total syntheses of premalbrancheamide,87 malbrancheamide,88 spiromalbramide,
89
 marcfortine C,90 notoamide T and its C-6-epimer,63 also now known to be a natural 
metabolite as described above.
As shown in Scheme 19, the reverse-prenylated tryptophan derivative 66 was prepared on 
multi-gram scale from commercially available 6-hydroxyindole.63,83,91 Key steps included a 
Danishefsky 9-BBN reverse-prenylation of 3-chloroindole species 59 (ref. 92 and 100) and 
Claisen-based rearrangement of the propargyl ether 62 to the requisite pyran 63. Somei–
Kametani93–96 gramine-based construction of the amino acid and protecting group 
adjustment furnished the key tryptophan derivative 66 that has been deployed in numerous 
total syntheses of the stephacidins and notoamides.
As described in Scheme 20, β-hydroxyproline ethyl ester 67 was coupled with tryptophan 
species 66 employing peptide coupling reagent BOPCl. This provided the incipient 
dipeptide, which was then subjected to removal of the N-Fmoc residue allowing spontaneous 
cyclization to dioxopiperazine 68. Mitsunobu dehydration directly led to the tautomerized 
azadiene species 8,97 that was stable enough to be isolated by PTLC and observable by 1H 
NMR, but spontaneously underwent IMDA cycloaddition to give stephacidin A and C6-epi-
stephacidin A as a 2.4 : 1, syn : anti mixture in 64% combined yield.67
Oxidation of synthetic stephacidin A with the Davis saccharin-derived oxaziridine (69)98 
directly provided the spiro-oxindole product, notoamide B.67 Asymmetric syntheses of 
stephacidins A, B, and notoamide B were reported in 2007, utilizing a facially-controlled 
intramolecular SN2´ reaction.99
Notably, (−)-stephacidin A was achieved in 17 steps with a 6% overall yield. (+)-Stephacidin 
B is accessed from (−)-stephacidin A totaling a synthesis of 19 steps with a 1% overall yield. 
Additionally, (+)-notoamide B can be synthesized from the (−)-enantiomer of stephacidin A 
via the single oxidative pinacol step in 65% yield.99
Grubbs, et al., have also been able to conscript the oxaziridine oxidation to a short, 
biomimetic synthesis of notoamide C, C3-epi-notoamide C and notoamide D as shown in 
Scheme 21.66 Using the same reverse-prenylated tryptophan species 66, coupling with (S)-
proline and cyclization provided a diastereomeric mixture of dioxopiperazines 72 and 73 
that were separated and oxidized with the Davis oxaziridine to provide notoamide C (28%), 
C3-epi-notoamide C (48%) and a small amount of notoamide D (together with the 
corresponding 2,3-epimer in 10% combined yield).66
Similarly, notoamide J was prepared as detailed in Scheme 22 deploying the same Davis 
oxaziridine oxidation of indole 76 to provide notoamide J as a 2 : 1 diastereomeric mixture.
92,100
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As detailed in Scheme 23, biomimetic total syntheses of the malbrancheamides have been 
successfully realized, deploying the same approach. In contrast to the stephacidin substrate, 
the Mitsunobu dehydration stops at the stage of dehydroproline derivative 81 that has to be 
treated with aqueous KOH in methanol at room temperature or below to effect 
tautomerization to the requisite azadiene that then suffers IMDA cycloaddition to give the 
cycloadducts 83 and 84 in a ~1 : 2 anti : syn diastereomeric ratio in good overall yields.88 
Reduction of the tertiary amide in the presence of the secondary amide was readily achieved 
using di-isobutyl aluminum hydride.88
This same approach was also successfully deployed to effect a concise, biomimetic total 
synthesis of marcfortine C as illustrated in Scheme 24.90 Readily available β-
hydroxypipecolic acid was coupled to reverse-prenylated tryptophan derivative 66 and 
carried through the analogous sequence deployed for the stephacidin A synthesis. The final 
spiro-oxindole oxidation required “protecting” the tertiary amine as the corresponding 
tosylate salt, which permitted smooth and diastereoselective oxidation and spiro-
rearrangement to D,L-marcfortine C. This synthesis required a total of fifteen steps from 
commercially available 6-hydroxyindole with an overall yield of 3.7%.90
The asymmetric biomimetic total synthesis of versicolamide B has also been achieved and is 
described in Scheme 25.101,102 Similar to the previous discussion, pinacol rearrangement of 
reverse prenylated indole 68 allows for formation of a set of spiro-oxindole diastereomers. 
Upon separation, they can consequently be converted into both enantiomers of versicolamide 
B via IMDA cycloaddition. The C3-epimer of (+)-versicolamide B, recently isolated by the 
Tsukamoto laboratories from A. taichungensis and now denoted as ent-Taichunamide E,30 
has thus also been achieved via this synthetic route (Scheme 25).
Synthetic, isotopically labeled samples of notoamide T and 6-epi-notoamide T were 
prepared by the biomimetic IMDA strategy as shown in Scheme 26.63 The doubly 13C-
labeled samples of notoamide T and 6-epi-notoamide T were deployed in the precursor 
incorporation experiments described above (Scheme 9, Fig. 8) revealing that 6-epi-
notoamide T is the biosynthetic precursor to versicolamide B and 6-epi-stephacidin A and 
provided the substrates from which the hitherto unobserved new metabolites were 
constructed from dormant tailoring genes.62–64 Efforts are underway to prepare optically 
pure samples of the individual enantiomers of 6-epi-notoamide T to more deeply interrogate 
the triggering mechanism for the expression of the dormant tailoring genes responsible for 
the biosynthesis of these new structures which were only produced in the presence of 
synthetic, racemic 6-epi-notoamide T.
For studies relevant to the biosynthesis of the paraherquamides, the IMDA strategy has also 
been applied to complete the total syntheses of both racemic and optically pure VM55599 
and diastereomeric congeners. As shown in Scheme 27, optically pure VM55599, a 
metabolite co-produced with paraherquamide A, was prepared by the IMDA cycloaddition 
of O-acyl azadiene species 111 generated under conditions reported by Liebscher.57
This synthesis enabled the confirmation of the absolute configuration of (−)-VM55599 as 
the original isolation of this natural, trace metabolite only assigned the relative 
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configuration. As Stocking, et al. had demonstrated by labeled precursor incorporation 
experiments that the biogenetic source of β-methylproline in paraherquamide A was (S)-
isoleucine,103 they had tentatively assigned the absolute stereostructure shown (Scheme 27).
104–106
 Culturing Penicillium fellutanum in a large format enabled the isolation of about 0.5 
mg of natural (−)-VM55599.107 The synthetic material obtained, which was also derived 
from (S)-isoleucine via the Hoffman–Loeffler–Freytag protocol, exactly matched the natural 
species.57 Of additional significance, diastereomer 112 was not detected as a reaction 
product from this laboratory IMDA cycloaddition, revealing that the intrinsic facial bias of 
this particular IMDA construction favors the VM55599 stereochemistry and not the 
paraherquamide108–111 stereochemistry. This provides corroborating, indirect evidence that 
the enzyme responsible for the key cycloaddition that constructs the 
bicyclo[2.2.2]diazaoctane core in paraherquamide biosynthesis, must organize the 
conformation of the putative azadiene (presumably the unacylated congener of 111) to favor 
the paraherquamide stereochemistry in both a highly diastereoselective and enantioselective 
fashion. Stocking, et al., have also developed a racemic, biomimetic synthesis of VM55599 
and the same group of diastereomeric congeners corresponding to 112–114 as illustrated in 
Scheme 28.58,112 In this instance, all four diastereomers were produced in the IMDA 
cycloaddition via 121, which permitted the preparation of an authentic specimen of pre-
paraherquamide by dii-sobutyl aluminum hydride reduction of 122. As both amino acid 
subunits 47 and 116 were prepared from glycine, this synthesis was adopted to prepare 
double 13C-labeled versions of 122–125, VM55599 and pre-paraherquamide that were used 
in precursor incorporation experiments.112
5. The dioxopiperazine/monooxopiperazine quandary
It was initially assumed that the bicyclo[2.2.2]diazaoctane ring systems that are common to 
the monooxopiperazine natural alkaloids, that includes the paraherquamides, marcfortines, 
asperparalines,113,114 and malbrancheamides, proceeded via biogenetic paths analogous to 
that of the dioxopiperazine families described in detail above, wherein a late-stage reduction 
of the tryptophan-derived carbonyl group was presumed to occur after the IMDA 
construction. This assumption has proven to be incorrect based on the following 
observations. As shown in Scheme 29, precursor incorporation studies with racemic, doubly 
13C-labeled 126, 127, VM55599 and pre-paraherquamide were conducted in cultures of 
Penicillium fellutanum, and only pre-paraherquamide incorporated into the paraherquamide 
A isolated from this experiment (0.73% incorporation).112 In particular, the observed lack of 
incorporation of 126 was puzzling, which was presumed as the biosynthetic precursor to pre-
paraherquamide.
Ding, et al., observed exactly the same phenomena in malbrancheamide biosynthesis as 
shown in Scheme 30. Again here, the biomimetic synthesis of pre-malbrancheamide to 
prepare doubly 13C-labeled isotopomers of 128 and premalbrancheamide was adopted.115 
When both substrates were presented to cultures of Malbranchea aurantiaca, only 
premalbrancheamide incorporated into malbrancheamide B (5.5% incorporation). The lack 
of incorporation of either dioxopiperazine species 126 and 128 begged the question as to 
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when and how the tryptophan-derived carbonyl group is reduced by a net four-electrons? 
The answer to this quandary came in the most elegant way.
When the NRPS modules from the paraherquamide and malbrancheamide biosynthetic gene 
clusters were sequenced, it was revealed that the tryptophan module contains a terminal 
reductase domain, as opposed to the condensation domains evident in both amino acid-
loading NRPS modules in notoamide biosynthesis. This is illustrated in Scheme 31.62 Thus, 
Li, et al., have devised a new biogenetic hypothesis that envisions reductive release of the 
pro–trp dipeptide from the NRPS module, by either a two-electron or four-electron process 
(the four-electron reduction is shown) providing species 131 (or, the corresponding aldehyde 
if the reductive release is a two-electron process) which is then reverse-prenylated and 
oxidized (for 131; or just reverse-prenylated for the two-electron process) to give key amino-
aldehyde intermediate 132 that should spontaneously cyclize to carbinolamine 133. 
Subsequent dehydration to 134 and tautomerization to azadiene species 135 would then 
allow for IMDA cycloaddition, directly providing pre-paraherquamide (R = Me) and pre-
malbrancheamide (R = H), respectively.62 This proposed biogenetic pathway explains why 
the dioxopiperazine species 126 and 128 did not incorporate as they are not pathway 
intermediates!
The gene clusters for the post-NRPS module tailoring enzymes that construct species 132 
merits additional scrutiny as the timing of the events leading from the NRPS module to the 
cycloadducts remains to be resolved.
6. Fungal producers of prenylated indole alkaloids
A large number of species of Penicillium and Aspergillus, both presently with 
approximately 400 described and accepted species116–119 are able to produce prenylated 
indole alkaloids, including penitrems, cyclopiazonic acid, aflavinins, paspalines 
fumigaclavines, janthitrems/shearinins, thiersindoles, fumitremorgins, roquefortines, 
rugulovasines etc.120,121 In Penicillium, these secondary metabolites are predominantly 
produced by species in subgenus Penicillium, but several producers are also found in 
subgenus Aspergilloides. While penitrems are restricted to subgenus Penicillium, the related 
shearinins are produced by species in both subgenera. Several species in Penicillium 
produce roquefortine C as the biosynthetic end-product, including P. expansum, P. 
griseofulvum, P. crustosum, P. hordei, P. robsamsonii, P. samsonianum, P. roqueforti, P. 
carneum and P. paneum, while other species accumulate meleagrin and oxalines, derived 
from roquefortine C, for example P. chrysogenum, P. rubens, P. oxalicum, P. compactum, P. 
concentricum, P. coprobium, P. glandicola, P. crystallinum and P. malodoratum.117,120,122 
Interestingly, neoxaline is also produced by several species in Aspergillus section Nigri, but 
only in the uniseriate species.123,124 None of these secondary metabolites have been found 
outside the genera Aspergillus and Penicillium, except that few species in Talaromyces can 
produce rugulovasines.116,125
The bicyclo[2.2.2]diazaoctane ring system containing prenylated indole alkaloids are more 
restricted in their distribution, but again most of them are produced by species of Penicillium 
and Aspergillus. The known exception is the malbrancheamides produced by Malbranchea 
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species,22 a species belonging to the Myxotrichaceae and unrelated to the Trichocomaceae. 
Since this species already produces the Penicillium and Aspergillus metabolite penicillic 
acid,126 there is a possibility that the fungus was indeed correctly identified as a Penicillium 
or Aspergillus. Most of these unique prenylated indole alkaloids are produced by both 
Aspergillus and Penicillium species except that the mangrovamides,127 brevianamides, 
chrysogenamide, paraherquamides and marcfortines have only been reported from 
Penicillium species, while the asperparalines, sclerotiamides, notoamides, versicolamides, 
avrainvillamides, stephacidins, and taichunamides have been recorded from Aspergillus 
species. However, chemotaxonomic investigations have shown that the mangrovamides and 
okaramines have been found in both genera (Frisvad, unpublished data). In Penicillium, the 
brevianamides are produced only by two species in subgenus Penicillium section Fasciculata 
(P. viridicatum) and subgenus Penicillium section Brevicompacta (P. brevicompactum).
120,122
 The marcfortines have until now only been found in Penicillium paneum in subgenus 
Penicillium section Roquefortorum.120,122 The paraherquamides have been found in 
Penicillium paraherquei10 (Penicillium section Lanata-Divaricata) and P. canescens 
(Penicillium section Canescentia) (originally determined as P. charlesii).11 Chrysogenamide 
was reported from P. chrysogenum,29 but the identity of the producing organisms has not 
been confirmed.
The producers of the related asperparalines (aspergillimides), avrainvillamides, notoamides, 
sclerotiamides, stephacidins, taichunamides, and versicolamides are produced by species in 
Aspergillus subgenus Circumdati sections Candidi, Circumdati, and Nigri, and in subgenus 
Nidulantes section Versicolores. Species producing those metabolites in section Candidi 
include A. subalbidus and A. taichungensis.128,129 Species in section Nigri producing 
aspergillamides include A. brunneoviolaceus (A. jiensis).124 In section Circumdati the 
species A. affinis, A. auricomus, A. bridgeri, A. melleus, A. ochraceus, A. ostianus, A. 
pallidofulvus, A. persii, A. salwaensis, A. sclerotiorum, A. sesamicola, A. subramanianii, A. 
westerdijkiae and A. westlandensis produce “Aspergamides”, which is a mixture of 
notoamides, avrainvillamides, stephacidins, and sclerotiamide.116 Finally, Aspergillus 
subgenus Nidulantes section Versicolores contains producers of “Aspergamides”: A. 
amoenus and A. protuberus,35 but “Aspergamides” could not be found in any species in 
section Nidulantes.130 Further studies will show whether the producing species in these 
sections of Aspergilli all have stereochemical diversity in their production of these 
compounds.
7. Conclusions
The biogenesis of prenylated indole alkaloid families containing the unique 
bicyclo[2.2.2]diazaoctane core, obtained from various genera of marine and terrestrial fungi 
has revealed a number of fascinating aspects of secondary metabolite biosynthesis. First, it is 
clear that the biosynthetic gene clusters responsible for directing the biosyntheses of these 
structurally alluring natural compounds are widely distributed in the biosphere. In particular, 
the orthologous pairs of marine and terrestrial fungi responsible for stephacidin and 
notoamide biosyntheses, have extensively interrogated the stereochemistry of these 
molecular frameworks in both a relative and absolute sense. A vast repertoire of tailoring 
genes is in evidence, and the experiments described in Scheme 9 and Fig. 8 reveal that many 
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dormant tailoring genes likely lie in reserve in the genomes of these complex organisms. It is 
particularly intriguing to ponder the speciation events that occurred at some time during the 
evolutionary history of these fungi that resulted in enantiomerically distinct secondary 
metabolite profiles. Very little is known about the adaptive advantage with which these 
secondary metabolites embellish the producing fungi as the biological activities of these 
natural alkaloids have been only superficially examined and demand further elucidation.
It is also now clear that Nature has, perhaps, “accidentally” created the 
bicyclo[2.2.2]diazaoctane ring system through the generation of reactive, achiral azadiene 
species (138, Scheme 32). The achiral intermediates are conformationally restricted in the 
chiral environment of the enzyme binding sites that generate these species, and thus 
orchestrates these reactive azadiene species to undergo highly enantio- and 
diastereoselective cycloadditions culminating in the formation of the natural substances 
constituted with the bicyclo[2.2.2]diazaoctane core. Our biomimetic laboratory IMDA 
reactions, which proceed smoothly at or below room temperature in organic or aqueous 
solvents, are very facile transformations that in the biochemical setting, only require pre-
organization of the pre-transition state conformations.
It is further noteworthy that, in the monooxopiperazine families, the predominant relative 
stereochemistry is syn- (all known paraherquamide alkaloids in this family are syn-; see Fig. 
1 and 4) and only a single absolute configuration is currently in evidence (with the exception 
of VM55599, a shunt metabolite of paraherquamide biosynthesis). To date, the only 
monooxopiperazine-producing fungi that construct the corresponding anti-diastereomeric 
series are Penicillium purpurogenum G59 (penicimutamides D and E; P. purpurogenum G59 
has been mischaracterized and is a Penicillium citrinum),15 Penicillium chrysogenum 
(chrysogenamide A)29 and Penicillium citrinum F53 (the recently described citrinalin C).146 
In stark contradistinction, the dioxopiperazine families display a broader range of relative 
and absolute stereochemistry, where a myriad of both syn- and anti-metabolites have been 
isolated in both enantiomeric forms. Most intriguing from an evolutionary perspective, the 
enantio-divergence evident in both marine- and terrestrial-producing fungi, provides for a 
very rich and unique opportunity to study molecular evolution of these organisms.
The application of whole-genome sequencing, bioinformatics analysis, cloning and 
functional expression of biosynthetic enzymes, synthesis of labeled pathway metabolites, 
precursor incorporation studies, structure determination of new metabolites and total 
syntheses of both new/undiscovered and known metabolites has been deployed to gain a 
deeper understanding of the secondary metabolome of marine and terrestrial fungi that 
produce these families of alkaloids. It should be noted that many laboratories in the synthetic 
community have published elegant, yet non-biomimetic total syntheses of numerous natural 
products in this family of alkaloids.41,46,47,57,58,66,67,85,86,88,90,95,97,99,102,108,115,131–146 
These efforts have been reviewed by Miller and Williams in 2009 (ref. 40) and additional 
total syntheses have appeared in the literature since 2009.138–146 Complete knowledge of the 
structural and stereochemical homologies and disparities among these compounds continues 
to motivate research into the synthesis, chemistry, biochemistry, genetics and biology of 
natural fungal metabolites. It is anticipated that exciting new chapters of these fascinating 
natural alkaloids remain to be written.
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Fig. 1. 
Structures of representative prenylated indole alkaloids isolated from fungi of the genera 
Aspergillus, Penicillium, and Malbranchea.
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Fig. 2. 
Structures of several prenylated indole alkaloids isolated from fungi and their stereochemical 
relationships.
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Fig. 3. 
Early suggestions of Sammes43 and Birch45 concerning the biogenesis of the 
bicyclo[2.2.2]diazaoctane ring system in the brevianamides.
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Fig. 4. 
Stereochemical outcomes of the oxidative isoprene cyclization across the two amino acid a-
carbons in the construction of the bicyclo [2.2.2]diazaoctane.62
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Fig. 5. 
Precursor incorporation results of [13C]2–notoamide E in A. protuberus MF297-2.68–71
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Fig. 6. 
Structures of notoamides L and N–P.26,27,65
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Fig. 7. 
Results of the incorporation experiment of [13C]2–[15N]2–notoamide S in A. amoenus 
NRRL 35660.77
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Fig. 8. 
Results of the incorporation experiments of [13C]2–(±)-notoamide T in a trace element 
solution (A), [13C]2–(±)-6-epi-notoamide T in a trace element solution (B), and (±)-6-epi-
notoamide T on trace element agar plates (C) in A. protuberus MF297-2.63,64
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Fig. 9. 
Prenylated indole alkaloids illustrating the syn- and anti-diastereomeric relative 
configurations isolated from A. protuberus MF297-2 and A. amoenus NRL 35660.26,28,30,61
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Fig. 10. 
Structures of the taichunamides isolated from A. taichungensis IBT19404.30
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Fig. 11. 
Mining and annotation of biosynthetic gene clusters of fungal indole alkaloids. 
Brevianamide (Aspergillus versicolor MF030, brn); chrysogenamide (Penicillium. 
alligativum, chr); notoamide A (A. protuberus MF297-2, not); malbrancheamide 
(Malbranchea aurantiaca RRC1813, mal); waikialoid A (Aspergillus sp., wai); 3-epi-
notoamide C (A. taichungensis IBT 19404, tai); oxaline (P. oxalicum F30, oxa); citrinalin (P. 
citrinum F53, cit); parahequamide A (P. fellutanum ATCC20841, phq); citrinadins (P. 
citrinum IBT 29821, cnd).62,84
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Fig. 12. 
Comparison of the biosynthetic gene clusters of the (+)-notoamide (Aspergillus amoenus) 
and ( )-notoamide (Aspergillus protuberus) producing fungi.83
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Scheme 1. 
Alternative brevianamide biogenesis proposed by Williams.49
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Scheme 2. 
Putative IMDA reactions in the oxidative enzymatic transformation from notoamide S.61
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Scheme 3. 
Structures of prenylated indole alkaloids isolated from A. protuberus MF297-2 and initial 
proposal regarding their possible biogenetic relationships.24,41,63,66–70
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Scheme 4. 
Possible biosynthetic pathways to notoamide E4 from notoamide E.68
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Scheme 5. 
Structures of notoamides M and Q and possible formation of the bicyclo[2.2.2]diazaoctane 
ring system, theoretically through notoamides M and Q.26,27,65
Klas et al. Page 39
Nat Prod Rep. Author manuscript; available in PMC 2018 August 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Scheme 6. 
Possible biosynthetic pathways to notoamides L (A) and O (B).27
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Scheme 7. 
Initial proposal for the enantiodivergent biogenesis of enantiomeric prenylated indole 
alkaloids with a bicyclo[2.2.2]diazaoctane core in A. protuberus MF297-2 and A. amoenus 
NRRL 35660.28,70
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Scheme 8. 
Possible biosynthetic pathways from deoxybrevianamide E to stephacidin A and potential 
precursors for IMDA reactions.74–76
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Scheme 9. 
Possible biosynthetic pathways to 6-epi-notoamide T3 and 6-epi-notoamide T4 from 6-epi-
notoamide T.62,64
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Scheme 10. 
Possible biosynthetic pathways of an enantiomeric mixture of 6-epi-stephacidin A and (+)-
versicoclamide B in A. amoenus NRRL 35660.61,64
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Scheme 11. 
Possible biogenesis of taichunamides B and E and versicolamide B from 6-epi-stephacidin 
A.30
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Scheme 12. 
Proposed facial specificities of IMDA reactions for metabolites in A. protuberus MF297-2 
(blue circles), A. amoenus NRRL 35660 (red triangles), and A. taichungensis IBT 19404 
(green squares). Major and minor metabolites in each fungus are represented with large and 
small symbols, respectively.30
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Scheme 13. 
Current understanding of (+)- and (−)-notoamide biogenesis in Aspergillus sp.63
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Scheme 14. 
Role of NotB in the conversion of notoamide E into notoamides C and D.77
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Scheme 15. 
First-generation biomimetic total synthesis of D,L-brevianamide B.85
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Scheme 16. 
Second generation biomimetic total synthesis of D,L-brevianamide B.86
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Scheme 17. 
Third-generation biomimetic total synthesis of D,L-brevianamide B.60,85
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Scheme 18. 
Theoretical calculations predicting transition state energies and predicted product 
diastereoselectivities at the B3LYP/6-31G* level.54
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Scheme 19. 
Synthesis of the reverse-prenylated tryptophan moiety.63,83,91–95
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Scheme 20. 
Biomimetic total synthesis of stephacidin A and notoamide B.67,97
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Scheme 21. 
Biomimetic total syntheses of notoamide C, C3-epi-notoamide C and notoamide D.66
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Scheme 22. 
Biomimetic total syntheses of notoamide J.92,100
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Scheme 23. 
Biomimetic total synthesis of the malbrancheamides.88
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Scheme 24. 
Biomimetic total synthesis of D,L-marcfortine C.90
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Scheme 25. 
Biomimetic total synthesis of (+)-versicolamide B and (−)-versicolamide B.101,102
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Scheme 26. 
Biomimetic total synthesis of D,L-notoamide T and D,L-6-epi-notoamide T.63
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Scheme 27. 
Biomimetic total synthesis of (−)-VM55599.57
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Scheme 28. 
Biomimetic total synthesis of D,L-VM55599 and D,L-pre-paraherquamide.58,112
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Scheme 29. 
Results of precursor incorporation studies in Penicillium fellutanum with isotopically 
labeled dioxopiperazine and monooxopiperazine substrates.112
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Scheme 30. 
Results of precursor incorporation studies in Malbranchea aurantiaca with isotopically 
labeled dioxopiperazine and monooxopiperazine substrates.115
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Scheme 31. 
Molecular architecture of the monooxopiperazine NRPS module and a hypothetical 
biogenetic pathway to pre-paraherquamide and pre-malbrancheamide.62
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Scheme 32. 
Unified biogenetic hypothesis for prenylated indole alkaloids containing the 
bicyclo[2.2.2]diazaoctane nucleus.53
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Klas et al. Page 67
Table 1
Select notoamide biosynthetic enzymes
Enzyme bp/aa Heterologous host Function Substrate
NotB 1563/456 E. coli FAD binding domain protein Notoamide E
NotB´ 1344/455 - FAD binding domain protein Notoamide E
NotC 1350/427 E. coli Prenyl transferase 6-Hydroxydeoxybrevianamide E
NotD 2025/621 A. oryzae Oxidoreductase (+)-Notoamide T
NotD´ 2025/612 - Oxidoreductase (−)-Notoamide T
NotE 6723/2241 - NRPS module Pro + Trp
NotF 1431/453 E. coli Reverse prenyl transferase Brevianamide F
NotG 1901/544 - Cytochrome P450 Deoxybrevianamide E
NotH 1836/502 - Cytochrome P450 Notoamide S
NotH´ 1836/499 - Cytochrome P450 Notoamide S
NotI 1423/434 E. coli FAD binding domain protein (+)-Stephacidin A
NotI´ 1423/433 E. coli FAD binding domain protein (−)-Stephacidin A
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